A Multinational, Randomised, Double-Blind, Placebo-Controlled Trial to Evaluate the Effect of Ticagrelor Twice Daily on the Incidence of Cardiovascular Death, Myocardial Infarction or Stroke in Patients With Type 2 Diabetes Mellitus (THEMIS - Effect of Ticagrelor on Health Outcomes in diabEtes Mellitus Patients Intervention Study)

drug protocol number
D513BC00001
drug sponsor
AstraZeneca
drug study
Ticagrelor
drug trial site
King Khalid University Hospital (Riyadh)
drug status
Ongoing
drug phase